Tennessee Senate Bill SB2556

Tennessee 2025-2026 Regular Session

• Introduced: 2/2/26

Caption

AN ACT to amend Tennessee Code Annotated, Title 39; Title 53; Title 63 and Title 68, relative to medications approved by the federal food and drug administration.

Summary

Senate Bill 2556 is designed to amend various sections of the Tennessee Code Annotated, specifically concerning medications approved by the federal Food and Drug Administration (FDA) that relate to women's health. The bill mandates the Tennessee Department of Health to compile and submit a report detailing medications approved by the FDA for women's health purposes. This report is to be submitted annually to both the speaker of the Senate and the speaker of the House of Representatives, starting from January 1, 2027. The intent behind this legislation is to ensure that the state maintains an up-to-date record of medications that affect women's health and to facilitate better health oversight. The impact of SB2556 on state law includes a potential enhancement of transparency regarding women's health medications, as well as increased accountability on part of the health department. By imposing a requirement for annual reporting, the bill seeks to encourage the Department of Health to stay informed about FDA-approved medications that could impact women's health. This could directly affect healthcare providers, hospitals, and pharmacies within Tennessee, as they may need to adjust their practices based on the information provided in these state reports. While the primary focus of the bill is to promote awareness and oversight of medications relevant to women, notable contention arises around the potential implications for healthcare services. Concerns have been expressed regarding how this reporting requirement may affect the accessibility of FDA-approved medications for women and the burden it places on the Department of Health in terms of resources and operational capacity. Critics may argue that additional regulatory measures could create hurdles rather than providing real benefits to healthcare delivery. In summary, the passage of SB2556 could represent a significant step forward in ensuring women's health medications are adequately monitored and reported by state authorities. Nevertheless, it is essential to balance these reporting requirements with the need for healthcare providers to have streamlined access to vital medications, ensuring that the health sector is not encumbered by excessive regulations.